NCT04575961View on ClinicalTrials.gov

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2028

Conditions
Ovarian CancerLow Grade Serous CarcinomaPrimary Peritoneal CarcinomaFallopian Tube Cancer
Interventions
DRUG

Pembrolizumab

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles

Trial Locations (2)

13353

Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin

45136

Kliniken Essen Mitte, Essen

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

North Eastern German Society of Gynaecological Oncology

OTHER